10:00 AM EST - Medicenna Therapeutics Corp. : Announced that the U.S. Food and Drug Administration (FDA) has cleared Medicenna’s investigational new drug (IND) application to expand the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study of MDNA11 (the “ABILITY Study”), the Company’s long-acting, “beta-only” IL-2 super-agonist, to clinical trial sites in the United States. The ABILITY Study is currently enrolling patients at clinical trial sites in Australia and regulatory submissions to further expand the trial to sites in Canada and the United Kingdom are expected to be completed this calendar year. Medicenna Therapeutics Corp.
shares T.MDNA are trading up $0.05 at $2.83.
